Highly stable pyrimidine-motif triplex formation at physiological pH values by a bridged nucleic acid analogue

Angewandte Chemie - International Edition

Volumn 46, Issue 23, 2007, Pages 4306-4309

  Rahman, S M Abdur ^a,b   Seki, Sayori ^a   Obika, Satoshi ^a   Haitani, Sunao ^a   Miyashita, Kazuyuki ^a   Imanishi, Takeshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

Bridged nucleic acids; Oligonucleotides; Synthesis design; Thermal stability; Triplexes

Indexed keywords

BRIDGED NUCLEIC ACIDS; PHYSIOLOGICAL PH VALUES; SYNTHESIS DESIGN; TRIPLEXES;

CHEMICAL BONDS; CONFORMATIONS; FURAN RESINS; NITROGEN COMPOUNDS; NUCLEIC ACIDS; PH EFFECTS;

OLIGONUCLEOTIDES;

NUCLEIC ACID; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMISTRY; CONFORMATION; PH; PHYSICAL CHEMISTRY; STEREOISOMERISM; SYNTHESIS; TEMPERATURE;

CHEMISTRY, PHYSICAL; HYDROGEN-ION CONCENTRATION; MOLECULAR CONFORMATION; NUCLEIC ACIDS; PYRIMIDINES; STEREOISOMERISM; TEMPERATURE;

EID: 34447278079     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200604857     Document Type: Article

References (44)

1. a) H. E. Moser, P. B. Dervan, Science 1987, 238, 645;
2. b) M. D. Frank-Kamenetskii, S. M. Mirkin, Annu. Rev. Biochem. 1995, 64, 65;
3. c) V. N. Soyfer, V. N. Potaman, Triple-Helical Nucleic Acids, Springer, New York, 1996, p. 220;
4. d) M. M. Seidman, P. M. Glazer, J. Clin. Invest. 2003, 112, 487;
5. e) S. Buchini, C. J. Leumann, Curr. Opin. Chem. Biol. 2003, 7, 717.
6. T. Imanishi, S. Obika, Chem. Commun. 2002, 1653.
7. S. Obika, D. Nandu, Y. Hari, K. Mono, Y. In, T. Ishida, T. Imanishi, Tetrahedron Lett. 1997, 38, 8735.
8. S. K. Singh, P. Nielsen, A. A. Koshkin, J. Wengel, Chem. Commun. 1998, 455.
9. a) S. Obika, Y. Hari, T. Sugimoto, M. Sekiguchi, T. Imanishi, Tetrahedron Lett. 2000, 41, 8923;
10. b) S. Obika, T. Uneda, T. Sugimoto, D. Nanbu, T. Minami, T. Doi, T. Imanishi, Bioorg. Med. Chem. 2001, 9, 1001;
11. c) H. Torigoe, Y. Hari, M. Sekiguchi, S. Obika, T. Imanishi, J. Biol. Chem. 2001, 276, 2354;
12. d) S. Obika, Y. Hari, M. Sekiguchi, T. Imanishi, Angew. Chem. 2001, 113, 2149;
13. Angew. Chem. Int. Ed. 2001, 40, 2079;
14. e) S. Obika, Y. Hari, M. Sekiguchi, T. Imanishi, Chem. Eur. J. 2002, 8, 4796.
15. a) K. Morita, C. Hasegawa, M. Kaneko, S. Tsutsumi, J. Sone, T. Ishikawa, T. Imanishi, M. Koizumi, Bioorg. Med. Chem. Lett. 2002, 12, 73;
16. b) M. Koizumi, K. Morita, M. Daigo, S. Tsutsumi, K. Abe, S. Obika, T. Imanishi, Nucleic Acids Res 2003, 31, 3267.
17. NC because the bridge between 2′-O and 4′-C is constituted by N and C atoms.
18. The other fully modified TFOs formed triplexes at around the physiological pH value, see: a) M. Bolli, C. Leumann, Angew. Chem. 1995, 107, 694;
19. Angew. Chem. Int. Ed. Engl. 1995, 34, 694;
20. b) C. Escudé C. Giovannangeli, J.-S. Sun, D. H. Lloyd, J-K. Chen, S. M. Gryaznov, T. Garestier, C. Hélène, Proc. Natl. Acad. Sci. USA 1996, 93, 4365;
21. c) B. Cuenoud, F. Casset, D. Husken, F. Natt, R. M. Wolf, K.-H. Altmann, P. Martin, H. E. Moser, Angew. Chem. 1998, 110, 1350;
22. Angew. Chem. Int. Ed. 1998, 37, 1288;
23. d) S. M. Gryaznov, H. Winter, Nucleic Acids Res 1998, 26, 4160;
24. e) N. Kumar, K. E. Nielsen, S. Maiti, M. Petersen, J. Am. Chem. Soc. 2006, 128, 14.
25. a) M. Petersen, J. Wengel, Trends Biotechnol. 2003, 21, 74;
26. b) J. S. Jespen, J. Wengel, Curr. Opin. Drug Discovery Dev. 2004, 7, 188;
27. c) B. Vester, J. Wengel, Biochemistry 2004, 43, 13233;
28. d) L. Wang, C. J. Yang, C. D. Medley, S. A. Benner, W. Tan, J. Am. Chem. Soc. 2005, 127, 15664.
29. A. A. Koshkin, V. K. Rajwanshi, J. Wengel, Tetrahedron Lett. 1998, 39, 4381.
30. We had to replace the benzyl groups with a cyclic disiloxy group because we experienced cleavage of the N-O bridged structure during debenzylation of the corresponding dibenzyl derivative of 9.
31. a) K. Shah, H. Wu, T. M. Rana, Bioconjugate Chem. 1994, 5, 508;
32. b) M. Scherr, C. Klebba, R. Häner, A. Ganser, J. W. Engels, Bioorg. Med. Chem. Lett. 1997, 7, 1791.
33. Similar triplex-to-single-strand dissociation was also reported recently by Leumann, see: S. Buchini, C. J. Leumann, Angew. Chem. 2004, 116, 4015;
34. Angew. Chem. Int. Ed. 2004, 43, 3925.
35. [5b]
36. m value of the corresponding ENA-TFO could not be determined because of the difficulties in purification of the TFO.
37. In the case of room temperature EMS A, the triplexes were warmed to room temperature after incubating at 4°C and kept at room temperature for two hours before applying onto the gel. The gel was run at room temperature at a constant voltage of 70 V.
38. [8e] Variation of triplex mobility was also noted by Roberts and Crothers, see: R. W. Roberts, D. M. Crothers, Science 1992, 258, 1463.
39. J. L. Asensio, R. Carr, T. Brown, A. N. Lane, J. Am. Chem. Soc. 1999, 121, 11063.
40. S. Rhee, Z.-J. Han, K. Liu, H. T. Miles, D. R. Davis, Biochemistry 1999, 38, 16810.
41. T. P. Prakash, A. Puschl, E. Lesnik, V. Mohan, V. Tereshko, M. Egli, M. Manoharan, Org. Lett. 2004, 6, 1971.
42. A. Mayer, A. Häberli, C. Leumann, Org. Biomol. Chem. 2005, 3, 1653.
43. C. H. Gotfredsen, P. Schultze, J. Feigon, J. Am. Chem. Soc. 1998, 120, 4281.
44. Rules for designing BNA-TFOs for optimum triplex-forming ability were described, see: B. W. Sun, B. R. Babu, M. D. Sørensen, K. Zakrzewska, J. Wengel, Biochemistry 2004, 43, 4160.